Rodman & Renshaw is out with its report today on Celgene CELG, initiating CELG at Market Outperform.
In its report, Rodman & Renshaw writes, "In our view, the stock is consolidating before a sustained move up that will be driven by the company's unmatched earnings leverage, influenced principally by increasing use of maintenance
Revlimid, share buy-backs, and data from studies of Revlimid and pipeline products, pomalidomide and apremilast."
Rodman & Renshaw has a $105 PT on CELG.
At the time of posting, shares of CELG were trading at $66.19, down 0.25% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in